Clinical trials: Hepatocellular Carcinoma Non-Resectable
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Trial name
- NCT02057874
- Testing
- 3 Tesla Magnetic Resonance Imaging, Magnevist® (Intravenous (IV) administration of MRI contrast agent)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hepatocellular Carcinoma
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already been treated once with another therapy.
- Trial name
- METIV-HCC (NCT01755767)
- Testing
- Tivantinib
- Where
- 112 sites in United States, Argentina and 14 more
- Volunteers
- 383 people
- Sponsor
- Daiichi Sankyo
Hepatocellular Carcinoma (HCC)
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
This Phase 3 study was a global, multicenter trial that randomly assigned participants to either tislelizumab or sorafenib as a first-line treatment for adults with advanced liver cancer (hepatocellular carcinoma) that could not…
- Trial name
- NCT03412773
- Testing
- Tislelizumab, Sorafenib
- Where
- 122 sites in United States, China and 9 more
- Volunteers
- 684 people
- Sponsor
- BeiGene
Hepatocellular Carcinoma
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of…
- Trial name
- HIMALAYA (NCT03298451)
- Testing
- Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2)
- Where
- 160 sites in United States, Brazil and 15 more
- Volunteers
- 1,324 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma, Liver Cancer
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
The primary objective will be to assess progression-free survival (PFS) measured at 16 weeks following initiation of therapy with the combination of Avastin and erlotinib in patients with unresectable hepatocellular carcinoma…
- Trial name
- NCT00242502
- Testing
- Bevacizumab (Avastin), Erlotinib
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Cancer
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00335829
- Testing
- bevacizumab, chemotherapy, embolization therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Yale University
Hepatocellular Carcinoma
Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma
This is a single-arm phase II trial of Pembrolizumab (Keytruda) in patients with advanced, unresectable hepatocellular carcinoma.
- Trial name
- NCT02658019
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Lynn Feun, MD
Cancer of the Liver, Liver Cancer
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
The working hypothesis is that oral administration of an attenuated strain of Salmonella typhimurium is safe and efficacious for patients with unresectable hepatic metastasis from a solid tumor cancer.
- Conditions
- Cancer of the Liver, Liver Cancer, Hepatoma, Liver Neoplasms
- Trial name
- NCT01099631
- Testing
- Salmonella typhimurium
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard of care in adult subjects with unresectable or metastatic hepatocellular carcinoma (HCC).
- Trial name
- MEDI-573-1028 (NCT01498952)
- Testing
- MEDI-573 (1 of 3 doses), Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- MedImmune LLC
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00427973
- Testing
- cediranib maleate, laboratory biomarker analysis, computed tomography
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
This phase I/II trial is studying the side effects and best dose of belinostat and to see how well it works in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00321594
- Testing
- belinostat
- Where
- 2 sites in United States, Singapore
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma (HCC)
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable…
- Trial name
- NCT01761266
- Testing
- Lenvatinib, Sorafenib
- Where
- 186 sites in United States, Australia and 19 more
- Volunteers
- 954 people
- Sponsor
- Eisai Limited
Hepatocellular Carcinoma, Hepatoma
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS).
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
- Trial name
- SOLACE (NCT02460991)
- Testing
- DEB-TACE, Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Boston Scientific Corporation
Liver Cancer
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma
In this study the investigators will be studying the effects of proton beam radiation therapy. This is a very accurate kind of treatment that has been shown to affect less normal tissue than a photon radiation beam.
- Trial name
- NCT00976898
- Testing
- Proton Beam Irradiation
- Where
- 4 sites in United States
- Volunteers
- 83 people
- Sponsor
- Massachusetts General Hospital
Carcinoma, Hepatocellular, Biliary Tract Cancer
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Phase I study of RO7119929 given orally to participants with unresectable advanced or metastatic primary liver cancers and other solid tumors with predominant liver involvement.
- Conditions
- Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer, Liver Metastases
- Trial name
- NCT04338685
- Testing
- RO7119929, Tocilizumab
- Where
- 10 sites in United States, Denmark and 4 more
- Volunteers
- 55 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma (HCC)
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied.
- Trial name
- NCT00355238
- Testing
- brivanib (active)
- Where
- 37 sites in United States, France and 6 more
- Volunteers
- 137 people
- Sponsor
- Bristol-Myers Squibb
Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
This randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with liver cancer that has spread to nearby tissue or…
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT01015833
- Testing
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- 673 sites in United States, Canada and 1 more
- Volunteers
- 356 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Hepatocellular Carcinoma
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned.
- Trial name
- STOP-HCC (NCT01556490)
- Testing
- TheraSphere
- Where
- 94 sites in United States, Belgium and 9 more
- Volunteers
- 526 people
- Sponsor
- Boston Scientific Corporation
Liver Cancer
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524316
- Testing
- doxorubicin hydrochloride, sunitinib malate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute